Clinical experience with CD64-directed immunotherapy. An overview

Cancer Immunology Immunotherapy

Volumn 45, Issue 3-4, 1997, Pages 210-215

  Curnow, Randall T ^a  

^a MEDAREX INC   (United States)

Author keywords

Cancer; CD64; ITP; MDX 33; MDX 447; MDX H210

Indexed keywords

BISPECIFIC ANTIBODY; CD64 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; MDX 33; MDX 447; MDX H210; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CHILL; CLINICAL TRIAL; COLORECTAL CANCER; DOSE RESPONSE; DRUG EFFICACY; DRUG SCREENING; FEVER; FLU LIKE SYNDROME; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; KIDNEY CARCINOMA; LIVER METASTASIS; MALIGNANT NEOPLASTIC DISEASE; MYALGIA; OVARY CANCER; PAIN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER;

ANTIBODIES, BISPECIFIC; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; HUMANS; NEOPLASMS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, IGG;

EID: 0030727901     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050435     Document Type: Article

References (9)

1. Atherton PJ, James ND, Wallace DMA, Cooke P, Jones J (1997) An update on a phase II study to determine the biological effects of the BsAb MDX-H210 (anti-HER2/neu x anti-CD64) combined with GM-CSF in patients with advanced prostate and renal cell carcinomas that express HER2/neu. In: Proceedings of the 5th World Conference on Bispecific Antibodies, p 11a
2. Curnow RT, Pfister DG, Deo Y, Motzer RJ, Winston C, Keeperman KL, Malone T (1997) A phase I trial of bispecific antibody (BsAb) MDX447 without and with granulocyte colony-stimulating factor (G-CSF) in patients with adult solid tumors. Proc Am Soc Clin Oncol 16:438a
3. Deo YM, Graziano RF, Repp R, Winkel JGJ van de (1997) Clinical significance of IgG receptors and FcγR-directed immunotherapies. Immunol Today 18: 127
4. Ericson SG, Coleman KD, Wardwell K, Baker S, Fanger MW, Guyre PM, Ely P (1996) Monoclonal antibody 197 (anti-FcγRI) infusion in a patient with immune thrombocytopenia purpura (ITP) results in down-modulation of FcγRI on circulating monocytes. Br J Haematol 92:718
5. Fanger MW, Morganelli PM, Guyre PM (1993) Use of bispecific antibodies in the therapy of tumors. Cancer Treat Res 68:181
6. Guyre PM, Graziano RF, Vance BA, Morganelli PM, Fanger MW (1989) Monoclonal antibodies that bind to distinct epitopes on Fc gamma RI are able to trigger receptor function. J Immunol 143:1650
7. Kaufman PA, Guyre PM, Lewis LD, Valone FH, Memoli V, Wells WAA, Deo YM, Ernstoff MS, Fisher J, Mrozek-Orlowski M, Phipps K, Fanger MW (1996) HER-2/neu targeted immunotherapy: a pilot study of multi-dose MDX-210 in patients with breast or ovarian cancers that overexpress HER-2/neu and a report of an increased incidence of HER-2/neu overexpression in metastatic breast cancer. Tumor Targeting 2: 17
8. Kaufman PA, Guyre PM, Barth RJ, Lewis LD, Memoli VA, Curnow R, Deo Y, Harris R, Valone F, Wallace P, Wells W, Schned A, Fisher J, Waugh M, Phipps K, Mackay K, Fanger MW, Ernstoff MS (1997) Phase I trial of interferon gamma (IFNγ) and MDX-210 (anti-HER-2/neu x anti-FCγ12RI) in patients (pts) with metastatic carcinomas that overexpress HER-2/neu: preliminary findings. Proc Am Soc Clin Oncol 16: 430a
9. Valone FH, Kaufman PA, Guyre PM, Lewis LD, Memoli V, Deo Y, Graziano R, Fisher JL, Meyer L, Mrozek-Orlowski M, Wardwell K, Guyre V, Morley TL, Arvizu C, Fanger MW (1995) Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the protoconcogene HER-2/neu. J Clin Oncol 13:2281